Please ensure Javascript is enabled for purposes of website accessibility

Coronavirus Concerns Have Big Pharma Working From Home

By Cory Renauer - Updated Mar 10, 2020 at 12:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a COVID-19 cluster was traced to a Biogen meeting, two big Massachusetts pharmaceutical companies have asked employees to work remotely when possible.

Over the past few days, health officials in Cambridge, Massachusetts, reported on a cluster of 26 cases of COVID-19 that were traced to a Biogen (BIIB 0.26%) internal strategy meeting held in late February. In response, Takeda (TAK 0.80%), another global pharmaceutical company with a large presence in Cambridge, has told its employees to work from home whenever possible and to avoid all conferences over the next three months.

Two people from Indiana who attended the same meeting have tested positive, prompting Indianapolis-based Eli Lilly (LLY 4.12%) to take precautionary measures to prevent the coronavirus from spreading further. 

Bad for science

Work-from-home policies are great for anyone with a long commute, but they aren't so great for the advancement of scientific research. For example, the annual meeting of the American Association for Cancer Research is scheduled to begin on April 24, which means nobody from Takeda or Eli Lilly will be delivering presentations there in person. 

For larger biopharmaceutical companies, missing an opportunity to present data about clinical trials in front of conference audiences isn't the end of the world. But smaller biotechs that rely in part on those presentations to excite investors could find it harder than usual to attract capital.

Opportunity to shine

While the COVID-19 outbreak will be a net negative for the pharmaceutical industry, the months ahead will give internal messaging services from companies like Slack Technologies (WORK) and Microsoft (MSFT 3.42%) a chance to show their worth. 

Perhaps the largest beneficiary of big pharma's physical absence from upcoming conferences will be Zoom Video Communications (ZM 4.22%). Earlier this month, the teleconference service provider expanded its availability to 17 countries.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$211.93 (0.26%) $0.55
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$267.70 (3.42%) $8.84
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$325.62 (4.12%) $12.90
Zoom Video Communications Stock Quote
Zoom Video Communications
ZM
$122.64 (4.22%) $4.97
Slack Technologies, Inc. Stock Quote
Slack Technologies, Inc.
WORK
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
TAK
$13.84 (0.80%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.